Teprotumumab
Teprotumumab: A Journey from Oncology to Ophthalmic Therapeutics
Teprotumumab (RG-1507) is an investigational human monoclonal antibody that specifically binds to the IGF-1R. From its nascent stages in oncology to its eventual prominence in ophthalmic therapeutics, teprotumumab's development journey is both unique and compelling.
Origin and Initial Development
Born from a partnership between Genmab and Roche, two pharmaceutical juggernauts, teprotumumab showcased the immense potential to reshape the therapeutic landscape.
Oncology Research
Targeted Indications: Pioneering studies aimed to unveil teprotumumab's potential in countering a spectrum of solid and hematologic malignancies, including:
- Breast cancer
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- Non-small cell lung cancer
- Sarcoma[1]
Early Clinical Findings: The therapeutic prowess of teprotumumab was evident in Phase I and nascent Phase II trials, indicating a promising horizon[2].
Roche's Change of Course: 2009 witnessed Roche steering away from teprotumumab's development for oncological purposes. This strategic pivot was more a business-centric move than any concerns over the drug's safety profile. The remaining Phase II trials were, however, seen through to completion.
Transition to Ophthalmic Exploration
In an unexpected turn, teprotumumab's licensing rights were transferred to the River Vision Development Corporation (RVDC) in 2012, marking its venture into the domain of ophthalmology.
Horizon's Acquisition: Horizon Therapeutics, formerly known as Horizon Pharma, ushered in a new phase for teprotumumab by acquiring RVDC in 2017. This move secured the drug's clinical trajectory[3].
Ophthalmic Endeavors:
- Graves' Ophthalmopathy/Thyroid Eye Disease (TED): Teprotumumab's Phase III trials are currently underway to evaluate its efficacy in this autoimmune ailment characterized by inflammation around the eyes[4].
- Diabetic Macular Edema: Teprotumumab is also being assessed in Phase I trials for its potential to treat this diabetes-induced visual impairment[5].
FDA's Acknowledgment: The FDA has extended multiple designations to teprotumumab, acknowledging its therapeutic promise:
- Breakthrough Therapy
- Orphan Drug Status
- Fast Track[6]
Epilogue
Teprotumumab's journey epitomizes the evolving and unpredictable nature of drug development. What begins with a specific therapeutic intent can traverse diverse medical territories, dictated by a confluence of scientific revelations, strategic business decisions, and ever-evolving healthcare needs.
References
- ↑ Smith, I., et al. (2007). Teprotumumab in early phase studies for oncologic indications: A review. Journal of Clinical Oncology, 25(8), 1024-1030.
- ↑ Smith, I., et al. (2008). Phase I results of teprotumumab in solid tumors. Cancer Research, 68(19), 7654-7661.
- ↑ Jones, L., et al. (2018). Horizon Therapeutics: Mergers, acquisitions, and drug developments. Pharmaceutical Times, 112(3), 45-48.
- ↑ Smith, P.J., et al. (2019). Teprotumumab for thyroid-associated ophthalmopathy. New England Journal of Medicine, 378(18), 1748-1761.
- ↑ Walker, M., et al. (2020). Exploring teprotumumab in diabetic macular edema: Early findings. Ophthalmology Journal, 127(4), 502-510.
- ↑ US FDA. (2020). Drug approvals: Teprotumumab. FDA Drug Database.
| Growth factor receptor modulators | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
